We’ve recently updated our valuation analysis.

Paragon 28 Valuation

Is FNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FNA?

Other financial metrics that can be useful for relative valuation.

FNA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.1x
Enterprise Value/EBITDA-79.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does FNA's PS Ratio compare to its peers?

The above table shows the PS ratio for FNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.1x
ATRC AtriCure
6.4x15.0%US$2.0b
MLAB Mesa Laboratories
4.6x7.1%US$1.0b
LMAT LeMaitre Vascular
6.3x7.0%US$1.0b
TMCI Treace Medical Concepts
11.2x21.7%US$1.4b
FNA Paragon 28
8.2x18.9%US$1.4b

Price-To-Sales vs Peers: FNA is expensive based on its Price-To-Sales Ratio (8.2x) compared to the peer average (7.1x).


Price to Earnings Ratio vs Industry

How does FNA's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a

Price-To-Sales vs Industry: FNA is expensive based on its Price-To-Sales Ratio (8.2x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is FNA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FNA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.2x
Fair PS Ratio5.9x

Price-To-Sales vs Fair Ratio: FNA is expensive based on its Price-To-Sales Ratio (8.2x) compared to the estimated Fair Price-To-Sales Ratio (5.9x).


Share Price vs Fair Value

What is the Fair Price of FNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FNA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FNA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FNA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$16.75
US$28.60
+70.7%
12.0%US$32.00US$24.00n/a5
Jan ’24US$19.11
US$28.00
+46.5%
12.2%US$32.00US$24.00n/a6
Dec ’23US$19.50
US$27.20
+39.5%
11.7%US$32.00US$24.00n/a5
Nov ’23US$17.41
US$26.80
+53.9%
9.8%US$30.00US$24.00n/a5
Oct ’23US$17.82
US$26.80
+50.4%
9.8%US$30.00US$24.00n/a5
Sep ’23US$16.77
US$26.80
+59.8%
9.8%US$30.00US$24.00n/a5
Aug ’23US$18.42
US$25.00
+35.7%
17.9%US$30.00US$20.00n/a5
Jul ’23US$16.76
US$25.00
+49.2%
17.9%US$30.00US$20.00n/a5
Jun ’23US$18.00
US$25.00
+38.9%
17.9%US$30.00US$20.00n/a5
May ’23US$17.97
US$26.60
+48.0%
10.8%US$30.00US$23.00n/a5
Apr ’23US$18.25
US$26.60
+45.8%
10.8%US$30.00US$23.00n/a5
Mar ’23US$16.50
US$28.00
+69.7%
8.7%US$30.00US$25.00n/a5
Feb ’23US$15.40
US$29.20
+89.6%
7.3%US$31.00US$25.00n/a5
Jan ’23US$17.69
US$29.80
+68.5%
3.3%US$31.00US$28.00US$19.115
Dec ’22US$19.07
US$29.80
+56.3%
3.3%US$31.00US$28.00US$19.505

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies